What should I do if I develop resistance to Ustekinumab?

Ustekinumab (Ustekinumab) is a biologic agent mainly used to treat moderate to severe psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It reduces the inflammatory response by inhibiting the action of specific immune cytokines (IL-12 and IL-23), thereby improving the condition.

If drug resistance occurs after using ustekinumab, the doctor should be informed in time. Since everyone has a different constitution and has different drug resistance responses, the doctor will evaluate the patient's condition and check whether there are other factors leading to the development of drug resistance, such as the presence of other diseases, infections or drug interactions. For some patients, addressing these issues may improve the effectiveness of the medication. Your doctor may recommend combining ustekinumab with other medications to make treatment more effective. For example, other immunosuppressants, biologics, or small molecule targeted drugs can be used in combination. Your doctor may recommend adjusting the dose of ustekinumab or shortening the dosing interval to make it more effective. This may require further clinical evaluation and monitoring.

The generic drug Ustekinumab has been launched in China and is included in the medical insurance, and is only reimbursed for patients who meet the indications. The price of the 130mg/26ml intravenous injection preparation may be more than 5,000 yuan per box, and the price of the 90mg: 1.0ml*1 subcutaneous injection preparation may be more than 8,000 yuan per box. The price of the 130mg/26ml intravenous injection preparation of Ustekinumab sold overseas may be more than 2,000 US dollars per box, and the price of 45mg: 0.5ml*1 subcutaneous injection preparation per box may be more than 10,000 US dollars. There are currently no generic versions of ustekinumab produced in other overseas countries.